These findings are consistent with high MDM4 levels having oncogenic function in ovarian (Wynendaele et al., 2010) and prostate (Stegeman et al., 2015) cancers, and expand the studies of the first MDM4 SNPs identified in breast and ovarian cancers (Atwal et al., 2009). Here, MDM4 is linked to ovarian carcinoma.